Evidence map›Paper›PMID 20816848›Full record

ArticleMutation research2011

Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.

Manimalha Balasubramani, Chitose Nakao, Guy T Uechi, John Cardamone, Kathy Kamath, Kristen L Leslie, Raghavan Balachandran, Leslie Wilson, Billy W Day, Mary Ann Jordan

Abstract read
In one paragraph

Article in Mutation research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy.Annals of oncology : official journal of the European Society for Medical Oncology · 2013
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Manimalha BalasubramaniGenomics and Proteomics Core Laboratories, University of Pittsburgh, Pittsburgh, PA, USA.
Chitose Nakao
Guy T Uechi
John Cardamone
Kathy Kamath
Kristen L Leslie
Raghavan Balachandran
Leslie Wilson
Billy W Day
Mary Ann Jordan
University of California, Santa Barbara · USCore Laboratories (United States) · USUniversity of Pittsburgh · US

Funding

UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: BPCAUL1RR024153 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$73.9M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Mechanisms of Action of Anti-Mitotic DrugsR01CA057291 · NCI · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI JORDAN, MARY ANN · 1992 to 2007
$2.2M
NCATS NIH HHS UL1 TR000005NCI NIH HHS CA057291NCI NIH HHS R01 CA057291NCRR NIH HHS RR024153NCRR NIH HHS UL1 RR024153
6 · The paper itself

Abstract

Stathmin/oncoprotein 18, a protein that regulates microtubule dynamics, is highly expressed in a number of tumors including leukemia, lymphoma, neuroblastoma, breast, ovarian, and prostate cancers. High stathmin levels have been associated with the development of resistance to the widely used anti-cancer drug taxol ((®)Taxol, paclitaxel). The mechanisms of stathmin-mediated taxol resistance are not well-understood at the molecular level. To better understand the role of stathmin in taxol resistance, we stably overexpressed stathmin twofold in BT549 human breast cancer cells and characterized several cell processes involved in the mechanism of action of taxol. After stable overexpression of stathmin, neither the cell doubling time nor the mitotic index was altered and the microtubule polymer mass was reduced only modestly (by 18%). Unexpectedly, microtubule dynamicity was reduced by 29% after stathmin overexpression, resulting primarily from reduction in the catastrophe frequency. Sensitivity to taxol was reduced significantly (by 44%) in a clonogenic assay, and stathmin appeared to protect the cells from the spindle-damaging effects of taxol. The results suggest that in the stably stathmin-overexpressing clones, compensatory gene expression occurred that resulted in normal rates of cell proliferation and prevented the increase in catastrophe frequency expected in response to stathmin. Stathmin overexpression protected the cells from taxol-induced abnormal mitoses, and thus induced taxol resistance. Using offgel IEF/PAGE difference gel electrophoresis, we identified a number of proteins whose expression is reduced in the taxol-resistant stathmin-overexpressing cell lines, including proteins involved in the cytoskeleton and cell structure, the stress response, protein folding, glycolysis, and catalysis.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCell Line, TumorCell ProliferationDrug Resistance, NeoplasmElectrophoresis, Gel, Two-DimensionalFemaleHumansMicrotubulesMitosisMitotic IndexNeoplasm ProteinsPaclitaxelStathminUp-RegulationAntineoplastic AgentsNeoplasm ProteinsPaclitaxelStathmin

Identifiers

PMID20816848
PMCPMC3017223
OpenAlexW2009717588

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.